Atnahs Pharma buys AstraZeneca hypertension medicines.
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

AstraZeneca sells hypertension medicines to Atnahs Pharma

02 Mar 2020

AstraZeneca has divested global commercial rights to a total of five hypertension drugs to Atnahs Pharma for a consideration of $350m.

The divested medicines comprise Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol and chlorthalidone combination), Zestril (lisinopril) and Zestoretic (lisinopril and hydrochlorothiazide combination).

Inderal is a beta-blocker indicated to treat hypertension, tremors, angina and arrhythmias among other heart or circulatory conditions, but can also be used to reduce the severity and frequency of migraine.

Beta-blocker Tenormin is used for hypertension, arrhythmias and angina treatment, as well as to lower the risk of death after a heart attack.

Meanwhile, Tenoretic uses a combination of beta-blocker and diuretic (chlorthalidone) for the treatment of high blood pressure.

Zestril is designed as an angiotensin-converting enzyme (ACE) inhibitor to treat hypertension, congestive heart failure, diabetic-related conditions and hypertensive renal disease. It may also help improve survival after a heart attack.

Zestoretic is an ACE inhibitor and diuretic (hydrochlorothiazide), used to treat hypertension.

AstraZeneca signed an agreement to sell the drugs to Atnahs Pharma in January. The deal does not include the US and India rights previously sold.

Furthermore, AstraZeneca will retain the rights in Japan.

In 2018, the five medicines together generated $132m in annual sales in the markets covered by this agreement.

AstraZeneca BioPharmaceuticals executive vice-president Ruud Dobber said: “These are important established medicines and the divestment to Atnahs ensures they will continue to be available to patients.

“This transaction supports our strategy to realise value from our portfolio of non-core mature brands, enabling further investment in new medicines.”

In addition to the $350m instalment, AstraZeneca is also eligible for sales-contingent payments of up to $40m between 2020 and 2022.

Last month, AstraZeneca signed an agreement to sub-license Movantik’s global rights, except in Europe, Canada and Israel, to RedHill Biopharma.